We are thrilled to announce that Hera Biotech has been selected as a semi-finalist in the Hello Tomorrow Deep Tech Pioneers program. This recognition highlights our mission to revolutionize women’s health diagnostics through cutting-edge, pathology-based tools that empower clinicians and improve patient outcomes worldwide. At Hera, we are committed to transforming how conditions like endometriosis are diagnosed and managed. With the average time to diagnosis exceeding eight years, our work aims to shorten that timeline and improve the lives of millions of women. This recognition affirms our mission's importance and our technology's potential impact. We could not have done this without our leadership, Somer Baburek, MBA Cinzia Donato, and Paul Castella driving us forward. Together, we can push the boundaries of what’s possible in diagnostics and create sustainable solutions that improve health outcomes for all. For more information about the Hello Tomorrow Global Summit and the Deep Tech Pioneers program, visit their official website (in the comments). Hera is the future of hope, so let's build that hope—together.
Hera Biotech
Biotechnology Research
San Antonio, Texas 4,159 followers
Advancing the Standard of Care in Women's Health Diagnostics
About us
Our Vision: To be the world leader in understanding & addressing diagnostic & therapeutic deficiencies in women's health. Our Mission: Driven to advance the standard of care in women's health Our First Order of Business: Validate and commercialize the first non-surgical method of diagnosing, and staging, endometriosis.
- Website
-
http://www.herabiotech.com
External link for Hera Biotech
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- San Antonio, Texas
- Type
- Privately Held
- Founded
- 2020
- Specialties
- Women's Health, Diagnostics, Reproductive Health, Biotechnology, and Endometriosis
Locations
-
Primary
Get directions
San Antonio, Texas, US
Employees at Hera Biotech
-
Shayna Mancuso D.O., FACOG
Medical Director, Medical Affairs, Women’s Health: Astellas Pharma U.S., Inc.
-
Nameer Kirma
BASiC - A Core for Characterization of Single-Cell Genomics, Epigenomics and Biophysical Phenotype
-
Paul Castella
Senior Managing Partner at Targeted Technology Fund II
-
Ally Schott
Co-Founder & COO, Rogue Insights and Solutions | Distilling From Data to Design
Updates
-
We love seeing this coverage! We love it for the #patients, for the patient families, and for the #providers! Onward!!
Thank you Geri Stengel for covering such an important topic in #endometriosis and the work that Hera Biotech is doing to solve for the problem! Also, thank you to Kelly Neupert and Silvia Mah PhD, MBA for the powerful quotes that you provided for the article. So proud of our #team and bringing forward a truly scientific and mechanistic approach to this debilitating disease!
-
Looking for top-tier leadership in women's health? Don't miss the opportunity to meet with Somer Baburek, MBA, and/or Cinzia Donato when you're at HLTH USA next week! Also, don't miss Somer's presentation at The Cedars-Sinai Accelerator Demo Day on Tuesday the 22nd at 2 pm, you can find it on the agenda! Viva #LasVegas & Viva #WomensHealth
So proud to represent Hera Biotech and The Cedars-Sinai Accelerator at HLTH USA alongside Cinzia Donato this coming week! Hera is currently raising, so we're looking to meet with anyone who is looking for opportunities in women's health! You can book time with us here: https://lnkd.in/gdsKFJXc See you all next week!
-
-
We always enjoy listening to Somer Baburek, MBA discuss the importance of investing in hard science solutions in women's health! Here, here! Be sure to check her out on this incredible episode of the This is Women's Work podcast!
I had such an amazing time speaking with Nicole Kalil and am so excited to have my episode of This is Women's Work podcast live! Always exciting to have the opportunity to talk about #womenshealth and where we need to be #investing! Link in the comments so you can give it a listen!
-
-
So excited to have our company highlighted along with our comrade Healthplus.ai! Cohort 10 is here to change how diagnosis is done!
The predictive and diagnostic tools created by Class 10 address some of the most prevalent problems for everyday patients. Today, we are excited to introduce Healthplus.ai and Hera Biotech. Healthplus.ai is enabling proactive surgery care through personalized complication predictions. Healthplus.ai's CE IIa certified solution, PERISCOPE®, is an AI-based decision support tool that highly-accurately predicts infection risks using existing EHR data, facilitating early intervention, eliminating unnecessary hospital stays, and reducing readmissions. Healthplus.ai uses real-time data along with validated & locally recalibrated machine learning algorithms to integrate with the existing workflow to aid clinical staff, delivering proactive and individualized care. Hera Biotech offers the world’s first non-surgical test for endometriosis, the number one cause of female infertility. Hera's test, MetriDx™, provides definitive diagnosis and staging of endometriosis through tissue-based analysis. MetriDx™ measures the expression patterns of an endometriosis-specific gene panel. Hera Biotech's patent-protected panel is heavily based on the expression profiles of a gene set implicated in a number of other invasive processes. Hera Biotech primarily serves the OB/GYN and fertility solutions markets with its innovative diagnostic tool. #CSaccelerator #healthinnovate #healthaccelerator #HIT #healthdisruptors #CSAclass10
-
-
So proud to see our CEO Somer Baburek, MBA, and our team at Hera being recognized for our work in #womenshealth!
📢 Spotlight on pioneers in "AI applications in women's health" 📢 We are excited to share our newest report, "AI Applications in Women's Health". In this report, we highlight companies paving the way for better health outcomes for women by harnessing AI. Hera Biotech: Somer Baburek, MBA and the team at Hera are powering endometriosis diagnosis with AI. Evvy: Priyanka Jain and the team at Evvy have developed vaginal microbiome testing. Oviva Therapeutics: Daisy Robinton, PhD and the team at Oviva are increasing ovarian healthspan. WHOOP: Will Ahmed and the team at Whoop are supporting women with wearables to track their wellbeing. 🔗 Download the complete report to dive into details about the latest in the landscape of AI in women's health: https://lnkd.in/eKvt_HXq #femtech #DrB #Womenshealth #AI #Marketinsights
-
-
Hey, hey, hey!!! So proud that our company was selected from >1000 applicants as one of the 10 to participate in this, Class 10! Here we goooo!
Please join us in welcoming and congratulating the digital health companies selected to join the Cedars-Sinai Accelerator's prestigious Class 10! From curated business sessions to meetings with various healthcare professionals from Cedars-Sinai and beyond, the Accelerator Program will offer these companies countless opportunities to promote their innovative solutions and learn how they can make an impact in the current healthcare landscape. Learn more about each company by reading the article below or checking out their company page. Class is almost in session! Welcome Class 10! Elaborate Fraiya Ltd Healthplus.ai Hera Biotech iCardio.ai Kinexcs Momentum Health Neu Health NOMA AI Pulse Charter Connect #CSaccelerator #healthinnovate #healthaccelerator #HIT #healthdisruptors #CSAclass10
Cedars-Sinai Accelerator Welcomes 10th Class of Health-Tech Startups
cedars-sinai.org
-
At Hera, we are incredibly passionate about improving definitive diagnostics for endometriosis, taking it from surgical to simple, but always recognizing the importance of a tissue-based connection with a tissue-based disease. We also see the importance of elucidating the whole burden of endometriosis. It's easy to minimize the impact of something that is not directly affecting you or a loved one. We believe that endometriosis harms the whole of society, not just those that it immediately impacts, and we have dedicated precious resources to the research needed to prove this. We are so very pleased to present our 4th white paper in this series. We cannot thank Mark Gannott, A/Prof Mike Armour, Ryan Castle, Diana Nancy Contreras, MD MPH, Ally Schott, and Emma Ricci-De Lucca, the team that worked to get this paper done. This one was a heavy lift and they delivered something so data-driven, yet so easy to digest. Thank you to each of you, we are so appreciative of your dedication. Please view the visual executive summary below and read the new Hera white paper here: https://lnkd.in/gwt8RzuC #endometriosis #womenshealth #biotech #surgicaltosimple #socialdeterminantsofhealth
-
-
-
-
-
+4
-
-
Behind every brave smile, there's a silent struggle. Living with endometriosis is more than painful periods; it's battling through work, school, and daily life. #EndometriosisAwareness #FromSurgicalToSimple
-
-
Understanding these connections is crucial for advancing women's health research. Together, let's raise awareness and support ongoing studies. 💗🔬 #WomenHealth #FromSurgicalToSimple
-